NXTC Market Analysis
Overview
Price chart · mood · technical indicatorsFundamentals
Updated daily after market closeValuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 0.97
- P/S (TTM)
- 9.52
- EV/EBITDA
- 0.51
Profitability & growth
- ROE (TTM)
- -111.2%
- Operating margin
- 0.0%
- Revenue growth YoY
- -100.0%
- Dividend yield
- —
- Beta
- 1.58
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
News & Sentiment
50 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
About NextCure Inc
Company profileNextCure, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of novel immunomedicines to treat cancer and other diseases related to the immune system by restoring normal immune function. The company is headquartered in Beltsville, Maryland.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 9000 VIRGINIA MANOR ROAD, BELTSVILLE, MD
- Fiscal year end
- December
- Latest quarter
- Dec 31, 2025
Educational content · Not investment advice or recommendations
We're educators, not advisors. Your decisions are your own. Disclaimer
I'm your AI thinking companion for the markets — I can help you explore and learn, but I'm not a financial advisor. Everything here is educational. Disclaimer